DEF 14A: Bolt Biotherapeutics Sets Date for 2024 Annual Stockholders Meeting, Outlines Key Proposals

Bolt Biotherapeutics announces its 2024 Annual Meeting of Stockholders to be held virtually on June 12, 2024, to elect directors and ratify the selection of its independent accounting firm.

Summary

• Bolt Biotherapeutics will hold its 2024 Annual Meeting of Stockholders online on June 12, 2024, at 11:00 a.m. Pacific Time.
• Stockholders of record as of April 15, 2024, are eligible to vote.
• The meeting will address the election of two Class III directors, Kathleen LaPorte and Nicole Onetto, to serve until the 2027 Annual Meeting.
• The stockholders will also vote to ratify the selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the year ending December 31, 2024.
• The Board of Directors recommends voting 'FOR' the election of the director nominees and 'FOR' the ratification of PricewaterhouseCoopers LLP.
• Stockholders can vote online, by phone, or by mail, as instructed in the Notice of Internet Availability of Proxy Materials.
• The company had 38,127,740 shares of common stock outstanding and entitled to vote as of April 15, 2024.
• A quorum requires the presence of a majority of the voting power of the outstanding shares.
• The Board met six times and its committees met nine times during the year ended December 31, 2023.
• The company's amended and restated certificate of incorporation limits the liability of directors to the fullest extent permitted by Delaware law.

Sentiment

Score: 7

Explanation: The document is primarily procedural and informational, with a neutral to slightly positive sentiment due to the standard corporate governance practices being followed.

Positives

• The Board is actively engaged in risk oversight, with committees addressing risks in their respective areas.
• The company has a code of business conduct and ethics in place for directors, officers, and employees.
• Stockholders have multiple options for voting, including online, phone, and mail.
• The company provides detailed information on director compensation and equity ownership.
• The audit committee is comprised of independent directors and has an audit committee financial expert.
• The company has adopted a related person transaction policy to ensure fair dealings.

Negatives

• Dr. Miller's term as director will expire at the 2024 Annual Meeting of Stockholders and he is not standing for re-election.
• Following the Annual Meeting the size of our Board will be reduced to nine directors.

Risks

• The limitation of liability and indemnification provisions in the company's charter and bylaws may discourage lawsuits against directors.
• A stockholder's investment may be adversely affected to the extent that the company pays the costs of settlement and damage awards against directors and officers as required by these indemnification provisions.
• The company is subject to cybersecurity risks, which are overseen by the audit committee.

Future Outlook

The Board knows of no other matters that will be presented for consideration at the Annual Meeting; however, the proxies are authorized to vote on such matters in accordance with their best judgment.

Industry Context

This proxy statement is a standard part of corporate governance, ensuring shareholders have the information needed to make informed decisions on key company matters. The virtual meeting format reflects a growing trend in corporate governance to increase accessibility and reduce costs.

Comparison to Industry Standards

• The director compensation policy is in line with industry standards, providing a mix of cash and equity compensation.
• The company's related person transaction policy aligns with best practices in corporate governance.
• The use of independent compensation consultants is a common practice among publicly traded companies to ensure fair and competitive executive compensation.
• The company's risk oversight structure, with the Board and its committees overseeing risk management, is a typical approach for companies of its size and complexity.

Related Party Transactions

• The company has a license agreement with Stanford University, where Dr. Engleman, a board member, is a professor and co-inventor of some of the licensed patents.
• The company has entered into an amended and restated investor rights agreement with certain holders of its capital stock, including entities affiliated with Citadel Multi-Strategy Equities Master Fund Ltd., Pivotal bioVenture Partners LLC, Sofinnova Investments, Inc. and Vivo Capital and including certain members of, and affiliates of, our directors.

Stakeholder Impact

• Shareholders are asked to vote on key decisions affecting the company's governance and financial oversight.
• The election of directors will shape the strategic direction and oversight of the company.
• The ratification of the independent accounting firm ensures the integrity of the company's financial reporting.
• Employees are subject to a code of business conduct and ethics.
• Executive officers are eligible for severance benefits under certain circumstances.

Next Steps

• Stockholders to vote on the proposals before the Annual Meeting.
• The company to hold the Annual Meeting on June 12, 2024.
• The company to file a Form 8-K with the final voting results within four business days following the Annual Meeting.
• The nominating and corporate governance committee will give full consideration to the adoption of a formal process for stockholder communications with our Board and, if adopted, publish it promptly and post it to our website.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Board of Directors, Stockholders, Director Election, PricewaterhouseCoopers, Audit Committee, Corporate Governance, Bolt Biotherapeutics, Voting